Lurasidone HCl

DRUG14 trials

Sponsors

Sumitomo Pharma America, Inc., NeuroRx, Inc., Sumitomo Pharma (Suzhou) Co., Ltd.

Conditions

Bipolar DepressionBipolar I DepressionMale, Healthy Normal SubjectsSchizoaffective DisorderSchizophreniaSchizophrenia PatientsSchizophrenia, Schizoaffective Disorder, or Schizophreniform DisorderSuicidal Ideation

Phase 1

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

CompletedNCT01074632

Sumitomo Pharma America, Inc.Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

Start: 2009-05-31End: 2009-09-30Updated: 2011-09-08

Lithium Drug-Drug Interaction Study With Lurasidone HCl

CompletedNCT01074073

Sumitomo Pharma America, Inc.Schizophrenia

Start: 2008-08-31End: 2008-10-31Updated: 2011-09-08

Midazolam Drug-Drug Interaction Study With Lurasidone HCl

CompletedNCT01082263

Sumitomo Pharma America, Inc.Schizophrenia Patients

Start: 2008-10-31End: 2008-11-30Target: 24Updated: 2011-09-08

The Bioequivalence Of Two Different Lurasidone Formulations In Patients

CompletedNCT01082250

Sumitomo Pharma America, Inc.Schizophrenia

Start: 2008-07-31End: 2008-09-30Target: 52Updated: 2011-09-08

Rifampin Drug-Drug Interaction Study With Lurasidone HCl

CompletedNCT01082276

Sumitomo Pharma America, Inc.Male, Healthy Normal Subjects

Start: 2008-08-31End: 2008-08-31Updated: 2011-09-08

Phase 2

NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

CompletedNCT03395392

NeuroRx, Inc.Bipolar Depression, Suicidal Ideation and Behavior

Start: 2022-05-12End: 2024-03-30Updated: 2024-05-08

NRX101 Glx Biomarker Validation Study

CompletedNCT03402152

NeuroRx, Inc.Bipolar Depression, Suicidal Ideation

Start: 2018-11-01End: 2021-06-01Updated: 2022-08-09

Phase 3

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

CompletedNCT00549718

Sumitomo Pharma America, Inc.Schizophrenia

Start: 2007-10-31End: 2010-10-31Updated: 2014-06-11

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

CompletedNCT00641745

Sumitomo Pharma America, Inc.Schizoaffective Disorder, Schizophrenia

Start: 2008-03-31End: 2010-07-31Updated: 2015-06-22

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

CompletedNCT01143077

Sumitomo Pharma America, Inc.Schizoaffective Disorder, Schizophrenia

Start: 2010-06-30End: 2011-05-31Updated: 2013-04-17

A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder

CompletedNCT01143090

Sumitomo Pharma America, Inc.Schizoaffective Disorder, Schizophrenia

Start: 2010-08-31Updated: 2015-06-12

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

Active, not recruitingNCT03396068

NeuroRx, Inc.Bipolar Depression, Suicidal Ideation

Start: 2019-12-01End: 2024-12-31Target: 72Updated: 2024-01-19

A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression

TerminatedNCT04383691

Sumitomo Pharma (Suzhou) Co., Ltd.Bipolar I Depression

Start: 2020-12-11End: 2022-12-23Updated: 2023-01-17

Unknown Phase

The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

CompletedNCT04432688

Sumitomo Pharma (Suzhou) Co., Ltd.Schizophrenia

Start: 2020-12-01End: 2023-06-18Updated: 2024-04-18

Related Papers

NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial.

2023-08-1315 citations

Assessment of Negative Symptoms in Clinical Trials of Acute Schizophrenia: Test of a Novel Enrichment Strategy

Schizophrenia Bulletin Open2022-01-018 citations

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS.

2021-11-0917 citations

Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study

Neurology and Therapy2020-10-249 citations

Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.

2020-05-0513 citations

Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia

General Hospital Psychiatry2017-05-0513 citations

Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia

BMC Psychiatry2016-05-3110 citations

Metabolic syndrome in patients with schizophrenia receiving long-term treatment with lurasidone, quetiapine XR, or risperidone

European Psychiatry2016-03-011 citations

Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.

2014-02-239 citations

Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.

2013-02-0145 citations